Help Your Patients
Experience Growth

Boy and girl discuss soccer.

A Clinical Commitment

SKYTROFA® has been studied in over 300 children with GHD, including treatment‑naïve and treatment-experienced patients1‑3

SKYTROFA phase 3 program in pediatric GHD1‑4

Chart of Skytropha Phase 3 Program
STUDY DESIGNS

Experience Growth

Once-weekly SKYTROFA: Demonstrated higher LS mean AHV at week 52 in treatment-naïve children compared with a daily somatropin1,2

LS mean AHV and height SDS changes from baseline at week 52: Once-weekly SKYTROFA versus daily somatropin1,2*

* At week 52, patients receiving once-weekly SKYTROFA had an LS mean (SE) AHV of 11.2 (0.2) cm/year compared with 10.3 (0.3) cm/year for those receiving a daily somatropin, and a change from baseline in height SDS LS mean (SE) of 1.10 (0.04) compared with 0.96 (0.05).1,2
  • The treatment difference in LS mean AHV with SKYTROFA compared with daily somatropin was 0.9 cm/year1,2
    • 95% CI of 0.2 to 1.5 cm/year1,2
    • The weekly dose of hGH was equivalent to 0.24 mg hGH/kg/week for both SKYTROFA and daily somatropin1
  • The change in mean (SD) bone age from baseline to week 52 was similar with SKYTROFA (1.36 [0.87] years) and daily somatropin (1.35 [0.72] years)5

Sustained growth was achieved with SKYTROFA in treatment-naïve patients6

Patients treated with SKYTROFA had a greater increase from baseline in height SDS† compared with patients treated with a daily somatropin2‡

† LS mean by ANCOVA.2
‡ Patients treated with SKYTROFA and daily somatropin had an increase in height SDS from baseline (SE) of 1.10 (0.04) and 0.96 (0.05) at week 52, respectively. Estimated difference = 0.14 SDS.2

Once-weekly SKYTROFA makes dosing easy for patients and their healthcare professionals

LEARN MORE ABOUT CONVENIENT DOSING